Ray Kelleher is an accomplished neurologist and neuroscientist, company founder, and investor. As Managing Director at Cormorant Asset Management, he invests in private and public companies across all therapeutic areas. He also represents Cormorant on the boards of Arkuda Therapeutics, BiVACOR, and ONK Therapeutics as Director, and Chroma Therapeutics, Umoja Biopharma, Interius BioTherapeutics, Garuda Therapeutics, and DTx Pharma as Observer.
Ray received BS degrees in Biology and Literature from MIT, an MA in French from Harvard, and an MD and PhD in Cell Biology from Stanford, where he discovered the Mediator of transcriptional activation while working with Nobel Laureate Roger Kornberg. He conducted postdoctoral research at MIT with Nobel Laureate Susumu Tonegawa, where he discovered a key role for translational control in memory formation. He completed his internship in internal medicine and residency in neurology at the Massachusetts General Hospital and Harvard Medical School, and subsequently joined the faculty at MGH and HMS. Taking advantage of the generation and multidisciplinary analysis of gene-targeted mouse models, his laboratory has made important contributions to understanding the molecular and cellular basis of cognition and cognitive disorders. His work has been published in Cell, Nature, Neuron, PNAS, and elsewhere, and his research accomplishments have been recognized with national awards including the Pew Scholars Award in the Biomedical Sciences, the John Merck Scholars Award, and the NIH Independent Scientist Award.
Ray maintains an active clinical neurology practice at MGH specializing in neurodegenerative disorders, particularly Alzheimer’s disease and related dementias.